Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension

Rubin M. Tuder, Carlyne D. Cool, Mark W. Geraci, Jun Wang, Steven H. Abman, Laurel Wright, David Badesch, Norbert F. Voelkel

Research output: Contribution to journalArticle

608 Citations (Scopus)

Abstract

Prostacyclin is a powerful vasodilator and inhibits platelet adhesion and cell growth. We hypothesized that a decrease in expression of the critical enzyme PGI2 synthase (PGI2-S) in the lung may represent an important manifestation of pulmonary endothelial dysfunction in severe pulmonary hypertension (PH). Immunohistochemistry and Western blot analysis were used to assess lung PGI2-S protein expression, and in situ hybridization was used to assess PGI2-S mRNA expression. In the normal pulmonary circulation (n = 7), PGI2-S was expressed in 48% of small, 67% of medium, and 76% of large pulmonary arteries as assessed by immunohistochemistry. PPH (n = 12), cirrhosis-associated (n = 4) and HIV- associated PH (n = 2) lungs exhibited a marked reduction in PGI2-S expression, involving all size ranges of pulmonary arteries. Vessels with concentric lesions showed complete lack of PGI2-S expression. Congenital heart (n = 4) and CREST (n = 2) cases exhibited a more variable immunohistological pattern of PGI2-S expression. These results were complemented by in situ hybridization and Western blots of representative lung samples. We conclude that the different sizes of the pulmonary arteries express PGI2-S differently and that the loss of expression of PGI2-S represents one of the phenotypic alterations present in the pulmonary endothelial cells in severe PH.

Original languageEnglish (US)
Pages (from-to)1925-1932
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume159
Issue number6
StatePublished - 1999
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Lung
Pulmonary Artery
In Situ Hybridization
Western Blotting
Immunohistochemistry
prostacyclin synthetase
Pulmonary Circulation
Epoprostenol
Vasodilator Agents
Cell Adhesion
Fibrosis
Blood Platelets
Endothelial Cells
HIV
Messenger RNA
Enzymes
Growth

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Tuder, R. M., Cool, C. D., Geraci, M. W., Wang, J., Abman, S. H., Wright, L., ... Voelkel, N. F. (1999). Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 159(6), 1925-1932.

Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. / Tuder, Rubin M.; Cool, Carlyne D.; Geraci, Mark W.; Wang, Jun; Abman, Steven H.; Wright, Laurel; Badesch, David; Voelkel, Norbert F.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 159, No. 6, 1999, p. 1925-1932.

Research output: Contribution to journalArticle

Tuder, RM, Cool, CD, Geraci, MW, Wang, J, Abman, SH, Wright, L, Badesch, D & Voelkel, NF 1999, 'Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension', American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 6, pp. 1925-1932.
Tuder, Rubin M. ; Cool, Carlyne D. ; Geraci, Mark W. ; Wang, Jun ; Abman, Steven H. ; Wright, Laurel ; Badesch, David ; Voelkel, Norbert F. / Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. In: American Journal of Respiratory and Critical Care Medicine. 1999 ; Vol. 159, No. 6. pp. 1925-1932.
@article{d2548da581b04f1a87acb353091b9479,
title = "Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension",
abstract = "Prostacyclin is a powerful vasodilator and inhibits platelet adhesion and cell growth. We hypothesized that a decrease in expression of the critical enzyme PGI2 synthase (PGI2-S) in the lung may represent an important manifestation of pulmonary endothelial dysfunction in severe pulmonary hypertension (PH). Immunohistochemistry and Western blot analysis were used to assess lung PGI2-S protein expression, and in situ hybridization was used to assess PGI2-S mRNA expression. In the normal pulmonary circulation (n = 7), PGI2-S was expressed in 48{\%} of small, 67{\%} of medium, and 76{\%} of large pulmonary arteries as assessed by immunohistochemistry. PPH (n = 12), cirrhosis-associated (n = 4) and HIV- associated PH (n = 2) lungs exhibited a marked reduction in PGI2-S expression, involving all size ranges of pulmonary arteries. Vessels with concentric lesions showed complete lack of PGI2-S expression. Congenital heart (n = 4) and CREST (n = 2) cases exhibited a more variable immunohistological pattern of PGI2-S expression. These results were complemented by in situ hybridization and Western blots of representative lung samples. We conclude that the different sizes of the pulmonary arteries express PGI2-S differently and that the loss of expression of PGI2-S represents one of the phenotypic alterations present in the pulmonary endothelial cells in severe PH.",
author = "Tuder, {Rubin M.} and Cool, {Carlyne D.} and Geraci, {Mark W.} and Jun Wang and Abman, {Steven H.} and Laurel Wright and David Badesch and Voelkel, {Norbert F.}",
year = "1999",
language = "English (US)",
volume = "159",
pages = "1925--1932",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension

AU - Tuder, Rubin M.

AU - Cool, Carlyne D.

AU - Geraci, Mark W.

AU - Wang, Jun

AU - Abman, Steven H.

AU - Wright, Laurel

AU - Badesch, David

AU - Voelkel, Norbert F.

PY - 1999

Y1 - 1999

N2 - Prostacyclin is a powerful vasodilator and inhibits platelet adhesion and cell growth. We hypothesized that a decrease in expression of the critical enzyme PGI2 synthase (PGI2-S) in the lung may represent an important manifestation of pulmonary endothelial dysfunction in severe pulmonary hypertension (PH). Immunohistochemistry and Western blot analysis were used to assess lung PGI2-S protein expression, and in situ hybridization was used to assess PGI2-S mRNA expression. In the normal pulmonary circulation (n = 7), PGI2-S was expressed in 48% of small, 67% of medium, and 76% of large pulmonary arteries as assessed by immunohistochemistry. PPH (n = 12), cirrhosis-associated (n = 4) and HIV- associated PH (n = 2) lungs exhibited a marked reduction in PGI2-S expression, involving all size ranges of pulmonary arteries. Vessels with concentric lesions showed complete lack of PGI2-S expression. Congenital heart (n = 4) and CREST (n = 2) cases exhibited a more variable immunohistological pattern of PGI2-S expression. These results were complemented by in situ hybridization and Western blots of representative lung samples. We conclude that the different sizes of the pulmonary arteries express PGI2-S differently and that the loss of expression of PGI2-S represents one of the phenotypic alterations present in the pulmonary endothelial cells in severe PH.

AB - Prostacyclin is a powerful vasodilator and inhibits platelet adhesion and cell growth. We hypothesized that a decrease in expression of the critical enzyme PGI2 synthase (PGI2-S) in the lung may represent an important manifestation of pulmonary endothelial dysfunction in severe pulmonary hypertension (PH). Immunohistochemistry and Western blot analysis were used to assess lung PGI2-S protein expression, and in situ hybridization was used to assess PGI2-S mRNA expression. In the normal pulmonary circulation (n = 7), PGI2-S was expressed in 48% of small, 67% of medium, and 76% of large pulmonary arteries as assessed by immunohistochemistry. PPH (n = 12), cirrhosis-associated (n = 4) and HIV- associated PH (n = 2) lungs exhibited a marked reduction in PGI2-S expression, involving all size ranges of pulmonary arteries. Vessels with concentric lesions showed complete lack of PGI2-S expression. Congenital heart (n = 4) and CREST (n = 2) cases exhibited a more variable immunohistological pattern of PGI2-S expression. These results were complemented by in situ hybridization and Western blots of representative lung samples. We conclude that the different sizes of the pulmonary arteries express PGI2-S differently and that the loss of expression of PGI2-S represents one of the phenotypic alterations present in the pulmonary endothelial cells in severe PH.

UR - http://www.scopus.com/inward/record.url?scp=0033032949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033032949&partnerID=8YFLogxK

M3 - Article

C2 - 10351941

AN - SCOPUS:0033032949

VL - 159

SP - 1925

EP - 1932

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -